Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Illinois Tool Works Inc. (ITW) vs Zoetis Inc (ZTS) Price & Performance

Illinois Tool Works Inc.Trade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

Illinois Tool Works Inc. vs Zoetis Inc — how do they compare? Illinois Tool Works Inc. trades at $292.72 (market cap $83.49B), while Zoetis Inc trades at $72.99 (market cap $31.14B). The key difference: Illinois Tool Works Inc. is far larger — about 2.7× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.81%). Which is the better fit depends on your goals.

ITWZTS
Market Cap
$83.49B$31.14B
Sector
IndustrialsHealth
52-Week High
$299.60$156.76
52-Week Low
$241.07$71.91
Enterprise Value
$92.34B$38.70B
Dividend Yield
2.35%2.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Illinois Tool Works Inc.

ITW trades at $293.66, down 0.29% on the day, with a bullish technical signal supported by moving averages. The company maintains strong profitability with 19.39% net income margin and 104.65% ROE, though valuations appear elevated at P/E 26.55 and P/B 28.85. Recent Q2 2026 earnings beat expectations at $2.84 EPS, and management raised full-year guidance amid manufacturing sector recovery. The company announced a 7% dividend increase and $6 billion share repurchase program in August 2026.

Outlook remains positive with analyst consensus target of $314.25 offering 7% upside potential. Key catalysts include continued manufacturing recovery and margin expansion from the 80/20 program. Risks include premium valuation concerns and potential organic sales declines masked by currency gains. Institutional sentiment is mixed with 21% buy ratings versus 32% sell recommendations.

Zoetis Inc

Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.

The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Illinois Tool Works Inc.

Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.

Read more on ITW

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS